| Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript |
Omeros Corporation (OMER) Q1 2025 Earnings Conference Call Transcript |
seekingalpha.com |
2025-05-16 01:07:08 |
Czytaj oryginał (ang.) |
| Omeros Corporation Reports First Quarter 2025 Financial Results |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024. At March 31, 2025, we had $52.4 million of cash and short-term investments available for operations and debt servicing, a decrease. |
businesswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference. |
businesswire.com |
2025-05-12 21:05:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion. |
businesswire.com |
2025-05-12 14:35:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company's 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026 Convertible Notes for newly issued 9.50% Convertible Senior Notes due 2029, with a conversion. |
businesswire.com |
2025-05-12 12:41:00 |
Czytaj oryginał (ang.) |
| FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the Prescription Drug User Fee Act (PDUFA) has been assigned a target action date for the FDA de. |
businesswire.com |
2025-05-06 13:16:00 |
Czytaj oryginał (ang.) |
| Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight |
Omeros Corporation OMER on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). |
benzinga.com |
2025-04-11 19:06:33 |
Czytaj oryginał (ang.) |
| Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros' OncotoX program for AML consists of proprietary targeted. |
businesswire.com |
2025-04-10 13:10:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodies which initiate complement activation independent of the classical pathway, will be delivered by Prof. Wilhelm Schwaeble,. |
businesswire.com |
2025-04-08 13:00:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript |
Omeros Corporation (NASDAQ:OMER ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Jennifer Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman & CEO David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Steven Whitaker - VP, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcome to today's Earnings Call for Omeros Corporation. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-04-01 00:57:33 |
Czytaj oryginał (ang.) |
| Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include: Net loss for the fourth quarter of 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024. For the year ended December 31, 2024, net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117. |
businesswire.com |
2025-03-31 20:02:00 |
Czytaj oryginał (ang.) |
| Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings |
Omeros Corporation OMER will release its fourth-quarter financial results after the closing bell on Monday, March 31. |
benzinga.com |
2025-03-28 09:39:34 |
Czytaj oryginał (ang.) |
| Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of th. |
businesswire.com |
2025-03-26 11:15:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros' investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysi. |
businesswire.com |
2025-03-21 11:15:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us |
Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues. |
seekingalpha.com |
2025-02-24 18:44:15 |
Czytaj oryginał (ang.) |
| Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). These latest analyses, conducted. |
businesswire.com |
2025-02-20 11:10:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research. The following materials are now available at www.investor.omeros.com/presentations: The slides accompanying a presentation. |
businesswire.com |
2025-02-14 11:00:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolulu, Hawaii. Both presentations report real world outcomes from patients with hematopoietic stem cell transplant-associated t. |
businesswire.com |
2025-02-10 11:00:00 |
Czytaj oryginał (ang.) |
| Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges |
On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab. |
benzinga.com |
2024-12-19 14:28:33 |
Czytaj oryginał (ang.) |
| Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). Th. |
businesswire.com |
2024-12-19 11:15:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The zaltenibart abstracts are directed to the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening hem. |
businesswire.com |
2024-12-02 10:45:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Provides Update on Progress Toward BLA Resubmission |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In last week's quarterly earnings release and associated call, Omeros stated that it was awaiting feedback. |
businesswire.com |
2024-11-21 11:15:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript |
Omeros Corporation (NASDAQ:OMER ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald Serge Belanger - Needham & Company Operator Good afternoon, and welcome to today's conference call for Omeros Corporation. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-14 00:22:06 |
Czytaj oryginał (ang.) |
| Omeros Corporation Reports Third Quarter 2024 Financial Results |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8. |
businesswire.com |
2024-11-13 18:02:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the. |
businesswire.com |
2024-11-11 18:11:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript |
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President-Clinical Development Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-10 05:05:05 |
Czytaj oryginał (ang.) |
| Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conferen. |
businesswire.com |
2024-08-05 20:02:00 |
Czytaj oryginał (ang.) |
| Omeros Announces Webcast Details for Annual Meeting of Shareholders |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2024. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. A. |
businesswire.com |
2024-06-04 13:00:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has completed a series of strategic financial transactions, further strengthening its balance sheet and extending the maturity profile on a substantial portion of its debt from February 2026 to June 2028, while providing a secure source of capital to support potential commercialization of its lectin pathway inhibitor narsoplimab and flexibility to manage the remaining balance of 2026 convertible notes. Today, Om. |
businesswire.com |
2024-06-03 13:00:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation (OMER) Q1 2024 Earnings Call Transcript |
Omeros Corporation (NASDAQ:OMER ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steve Whitaker - Vice President-Clinical Development Nadia Dac - Chief Commercial Officer Catherine Melfi - Chief Regulatory Officer Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time all participants are in listen-only mode. |
seekingalpha.com |
2024-05-15 23:23:04 |
Czytaj oryginał (ang.) |
| Omeros Corporation Reports First Quarter 2024 Financial Results |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include. |
businesswire.com |
2024-05-15 20:02:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the. |
businesswire.com |
2024-05-10 12:50:00 |
Czytaj oryginał (ang.) |
| Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript |
Omeros Corporation (OMER) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-04-02 00:09:09 |
Czytaj oryginał (ang.) |
| Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the. |
businesswire.com |
2024-03-27 10:30:00 |
Czytaj oryginał (ang.) |
| Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade |
Hidden gems often remain undiscovered within the labyrinth of the stock market. Three stocks with massive upside stand out among the several alternatives as possible titans with significant upside potential. |
investorplace.com |
2024-03-17 12:02:00 |
Czytaj oryginał (ang.) |
| 3 Sleeper Stocks Under $15 Ready to Explode by 2029 |
In general, high-growth stocks and sleeper stocks under $15 are associated with valuation concerns. Let's forget inflated giants and overhyped darlings. |
investorplace.com |
2024-02-07 11:34:32 |
Czytaj oryginał (ang.) |
| Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust |
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States. OMIDRIA, a novel ophthalmic product for use in cataract and lens replacement surgery, was invented and first commercialized by Omeros. In December 2021, Omeros sold OMIDRIA and related business assets to Rayner Surgi. |
businesswire.com |
2024-02-01 11:11:00 |
Czytaj oryginał (ang.) |
| 7 Short-Squeeze Stocks That Are Screaming for Speculation |
While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative practice under a three-dimensional lens. |
investorplace.com |
2023-12-24 15:08:45 |
Czytaj oryginał (ang.) |